Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Gelofusine on 111In-DTPA-Lys40-Exendin 4 kidney uptake
2014-003006-33Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of gelatin in carbohydrate malabsorption and diabetes mellitus (DM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Renal uptake of 111In-DTPA-[K40]-Exendin 4. Started Feb 2015; status: completed.
02
Drugs
gelatin
03
Conditions
carbohydrate malabsorptiondiabetes mellitus (DM)
Beyond the preview
Go deeper on 2014-003006-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003006-33.